Shares of KemPharm Inc. (NASDAQ:KMPH) traded down 3.1% during mid-day trading on Thursday . The company traded as low as $5.00 and last traded at $5.03, with a volume of 107,391 shares traded. The stock had previously closed at $5.19.

A number of analysts have issued reports on the company. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Tuesday. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $11.00 price target on shares of KemPharm in a research report on Tuesday, June 14th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a research report on Sunday, May 8th.

The firm’s 50-day moving average is $4.24 and its 200 day moving average is $10.11. The company’s market capitalization is $76.16 million.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.36. On average, equities analysts anticipate that KemPharm Inc. will post ($1.78) EPS for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.